Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

83.18CHF
4:30pm BST
Change (% chg)

CHF1.38 (+1.69%)
Prev Close
CHF81.80
Open
CHF82.04
Day's High
CHF83.32
Day's Low
CHF82.00
Volume
4,421,290
Avg. Vol
4,401,171
52-wk High
CHF88.30
52-wk Low
CHF71.84

Latest Key Developments (Source: Significant Developments)

Novartis Proposes To Exit Grimsby UK Site By End Of 2020
11:58am BST 

Sept 25 (Reuters) - Novartis AG ::NOVARTIS PROPOSES TO EXIT GRIMSBY UK SITE BY END OF 2020 AS PART OF GLOBAL MANUFACTURING NETWORK TRANSFORMATION.SAYS 395 NOVARTIS EMPLOYEES AT THE GRIMSBY SITE ARE DIRECTLY AFFECTED BY DECISION.SAYS PROPOSED EXIT TO BE PHASED UNTIL 2020 END; OPTIONS INCLUDING DIVESTMENT, WHICH MAY POTENTIALLY ALLOW FACILITY TO STAY OPEN, TO BE CONSIDERED.SAYS ADDITIONAL CONTACTORS EMPLOYED THROUGH THIRD PARTIES MAY ALSO BE IMPACTED BY GRIMSBY SITE DECISION.SAYS GRIMSBY SITE EXIT DECISION IS PART OF GLOBAL REVIEW OF MANUFACTURING OPERATIONS AND IS NOT LINKED TO DECISION OF UK TO LEAVE EU.  Full Article

Novartis AG Says 1,000 Net Jobs To Be Cut In Swiss Locations
7:09am BST 

Sept 25 (Reuters) - Novartis AG ::SAYS PLANS TO CUT JOBS IN SWITZERLAND.SAYS PLANNED JOBS TO BE CUT OVER FOUR YEARS, TO RESULT IN NET SWISS JOB CUTS OF 1,000 POSITIONS.SAYS JOBS TO BE CUT IN SWISS LOCATIONS IN BASEL, STEIN, LOCARNO AND SCHWEIZERHALLE.  Full Article

Novartis - Positive CHMP Opinion For Sandoz' Biosimilar Pegfilgrastim
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Novartis AG ::SANDOZ RECEIVES POSITIVE CHMP OPINION FOR PROPOSED BIOSIMILAR PEGFILGRASTIM.SANDOZ SEEKS APPROVAL IN SAME INDICATION AS REFERENCE MEDICINE, FOR PREVENTION OF FEBRILE NEUTROPENIA, A SERIOUS SIDE EFFECT OF CANCER CHEMOTHERAPY.  Full Article

Novartis Wins Positive CHMP Opinion For Gilenya For MS In Children
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Novartis AG ::NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR GILENYA® FOR THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH MS, MARKING A MAJOR MEDICAL ADVANCE FOR YOUNG MS PATIENTS IN EUROPE.  Full Article

Novartis Wins Positive CHMP Opinion For Luxturna To Treat Rare Inherited Retinal Disease
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Novartis AG ::ANNOUNCES POSITIVE CHMP OPINION FOR ONE-TIME GENE THERAPY LUXTURNA® TO TREAT CHILDREN AND ADULTS WITH RARE INHERITED RETINAL DISEASE.  Full Article

Ubiome Appointed Joseph Jimenez To Its Board
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Novartis AG ::UBIOME - APPOINTED JOSEPH JIMENEZ, FORMER CEO OF NOVARTIS, TO ITS BOARD.  Full Article

Novartis Receives Health Canada Approval Of Its Car-T Cell Therapy, Kymriah I
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Novartis AG ::NOVARTIS RECEIVES HEALTH CANADA APPROVAL OF ITS CAR-T CELL THERAPY, KYMRIAH™ (TISAGENLECLEUCEL)I.NOVARTIS - HEALTH CANADA HAS APPROVED KYMRIAH FIRST CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T) THERAPY TO RECEIVE REGULATORY APPROVAL IN CANADA.  Full Article

Mylan Closes Deal With Novartis To Commercialize Certain Global Cystic Fibrosis Products
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Mylan NV ::MYLAN - CLOSED DEAL WITH NOVARTIS TO BUY WORLDWIDE RIGHTS TO COMMERCIALIZE GLOBAL CYSTIC FIBROSIS PRODUCTS CONSISTING OF TOBI PODHALER & TOBI SOLUTION.  Full Article

Novartis melanoma cocktail gets additional EU approval
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Novartis AG ::EUROPEAN COMMISSION APPROVES NOVARTIS COMBINATION THERAPY TAFINLAR® + MEKINIST® FOR ADJUVANT TREATMENT OF BRAF V600 MUTATION-POSITIVE MELANOMA.EC APPROVAL MARKS THIRD INDICATION IN EUROPE FOR LEADING BRAF/MEK INHIBITOR COMBINATION TAFINLAR + MEKINIST.  Full Article

Withdrawal of stent won't affect Alcon spinoff - Novartis
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Novartis AG ::SPOKESMAN SAYS WITHDRAWAL OF GLAUCOMA STENT WILL NOT AFFECT PLANS FOR ALCON SPINOFF TO SHAREHOLDERS IN 2019, WILL NOT CHANGE ALCON'S SALES TARGETS FOR FULL YEAR.  Full Article

Photo

Oil boost and Italy budget hopes support European shares

MILAN European shares closed higher on Tuesday boosted by gains among oil stocks and optimism over the Italian budget while British clothing retailer Next rallied after raising its profit guidance.